Skip to content
Catalyst

Ganoderma lucidumFinding

Ganoderma lucidum decreases alanine aminotransferase

lowersModerate evidenceFinding

01 · The sentence it was drawn from

“As shown in Table 3, among the safety parameters, the intervention group exhibited significantly lower levels of ALP (74.94 ± 12.68 U/L), TBA (3.20 ± 1.47 µmol/L), AST (21.00 ± 5.37 U/L), ALT (20.94 ± 6.52 U/L), GGT (23.19 ± 14.60 U/L), direct bilirubin (3.43 ± 1.12 µmol/L), and total bilirubin (13.00 ± 4.10 µmol/L) compared to the placebo group (ALP: 85.20 ± 24.57 U/L, TBA: 3.95 ± 1.92 µmol/L, AST: 24.17 ± 6.04 U/L, ALT: 33.13 ± 24.80 U/L, GGT: 4.20 ± 1.14 µmol/L, direct bilirubin: 25.69 ± 11.81 µmol/L, total bilirubin: 15.83 ± 5.35 µmol/L; p < 0.05).”
Quoted verbatim from Clinical Evaluation of Ganoderma lucidum Spore Oil for Triglyceride Reduction: A Randomized, Double-Blind, Crossover Study.
This finding among the 65 findings on its endpoint

Ganoderma lucidum

Alanine aminotransferase

lowers

Who
Adults aged 18 to 65 years with triglycerides of 1.70 to 2.25 mmol/L; 55 per arm analysed
Dose studied
3 softgel capsules twice daily, 0.5 g extract per softgel, approximately 3.0 g/day

Moderate evidencePMID 40077714 · 2025

02 · The study

Study
RCT
Duration
3 months

Evidence, by strength

  • strong
  • moderatethis finding
  • limited
  • very limited
  • insufficient

04 · To cite this finding

This address does not change

https://catalystproject.ai/e/01M6ZJAH7Q7E2HHGAPDPF4MZJS